We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Luxottica Group (LUX - Free Report) is the world leader in the design, manufacture and marketing of high quality eyeglass frames and sunglasses in the mid and premium priced market segments. The Manufacturing segment of the company offers its products under proprietary brands, such as Ray-Ban, Oakley, Vogue Eyewear, and Arnette; and licensed brands, including Giorgio Armani, Brooks Brothers, Burberry, Chanel, Coach, Michael Kors, Prada, Ralph Lauren, Tiffany & Co, Tory Burch, Valentino, Versace and more. The Retail Distribution segment operates prescription eyewear stores primarily under its retail brands, including LensCrafters, Sunglass Hut, OPSM, Laubman & Pank, Oakley, David Clulow, and GMO; and licensed brands, such as Sears Optical and Target Optical.
The company was founded in 1961, is based in Milan Italy and employs almost 80,000 people. The stock is the Bear of the Day after being downgraded to a Zacks Rank #5 (Strong Sell) and after the company cut 2016 guidance.
Luxottica is valued around $23 billion and has a Forward PE of 24. The stock sports Zacks Style Scores of “D” in Value, due to its high end valuation. The stock has not had a pleasant year as its down over 30% from its high last July at $74 a share, to now $48.50. While some investors might be buying the dip, the company’s last earnings report along with falling estimates might force most to wait.
Q2 results
Only July 25th the company actually beat on both the top and bottom line. However, Luxottica cuts its revenue outlook for fiscal year 2016, saying it now expects +2-3% instead of the previous +5-6%. They also cut net income to “inline” with fiscal year sales.
On a presentation the company said that the sun season is rebounding after a soft start, but investors weren’t impressed as the stock traded down after EPS. Since the report, the stock has been treading water and falling estimates aren’t helping the situation.
Estimate Revisions
Over the last 30 days, estimates have been revised lower for all time frames. For fiscal year 2016, the numbers have been taken down 13%, from $2.31 to $1.99. For 2017, estimates are now seen at $2.15, down from $2.34 or 8%.
A Better Option
If you’re looking at Luxottica as a medical supply play, then perhaps Haylard Health would be a better choice. Haylard is a Zacks Rank #1 (Strong Buy) that sells surgical and infection prevention products for the operating room. The company was founded in 2014, has 12,000 employees and is headquartered in Georgia.
The company has a market cap of $1.6 billion and a Forward PE of 20. The stock sports a Zacks Style Score of “B” in Value.
On August 3rd the company beat EPS by 9 cents and beat on revenue estimates. Revisions to earnings estimates have spiked higher over the last year. For fiscal year 2016, estimates have been revised 10% higher over the last month, while 2017 has seen a 9% jump.
Note:Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
So Where Are the Profitable Trades?
Be sure to short or avoid this Bear Stock of the Day. Now would you like to see Zacks' recommendations that have the best profit potential? Starting today, for the next month, you can follow all our private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bear of the Day: Luxottica Group (LUX)
Luxottica Group (LUX - Free Report) is the world leader in the design, manufacture and marketing of high quality eyeglass frames and sunglasses in the mid and premium priced market segments. The Manufacturing segment of the company offers its products under proprietary brands, such as Ray-Ban, Oakley, Vogue Eyewear, and Arnette; and licensed brands, including Giorgio Armani, Brooks Brothers, Burberry, Chanel, Coach, Michael Kors, Prada, Ralph Lauren, Tiffany & Co, Tory Burch, Valentino, Versace and more. The Retail Distribution segment operates prescription eyewear stores primarily under its retail brands, including LensCrafters, Sunglass Hut, OPSM, Laubman & Pank, Oakley, David Clulow, and GMO; and licensed brands, such as Sears Optical and Target Optical.
The company was founded in 1961, is based in Milan Italy and employs almost 80,000 people. The stock is the Bear of the Day after being downgraded to a Zacks Rank #5 (Strong Sell) and after the company cut 2016 guidance.
Luxottica is valued around $23 billion and has a Forward PE of 24. The stock sports Zacks Style Scores of “D” in Value, due to its high end valuation. The stock has not had a pleasant year as its down over 30% from its high last July at $74 a share, to now $48.50. While some investors might be buying the dip, the company’s last earnings report along with falling estimates might force most to wait.
Q2 results
Only July 25th the company actually beat on both the top and bottom line. However, Luxottica cuts its revenue outlook for fiscal year 2016, saying it now expects +2-3% instead of the previous +5-6%. They also cut net income to “inline” with fiscal year sales.
On a presentation the company said that the sun season is rebounding after a soft start, but investors weren’t impressed as the stock traded down after EPS. Since the report, the stock has been treading water and falling estimates aren’t helping the situation.
Estimate Revisions
Over the last 30 days, estimates have been revised lower for all time frames. For fiscal year 2016, the numbers have been taken down 13%, from $2.31 to $1.99. For 2017, estimates are now seen at $2.15, down from $2.34 or 8%.
A Better Option
If you’re looking at Luxottica as a medical supply play, then perhaps Haylard Health would be a better choice. Haylard is a Zacks Rank #1 (Strong Buy) that sells surgical and infection prevention products for the operating room. The company was founded in 2014, has 12,000 employees and is headquartered in Georgia.
The company has a market cap of $1.6 billion and a Forward PE of 20. The stock sports a Zacks Style Score of “B” in Value.
On August 3rd the company beat EPS by 9 cents and beat on revenue estimates. Revisions to earnings estimates have spiked higher over the last year. For fiscal year 2016, estimates have been revised 10% higher over the last month, while 2017 has seen a 9% jump.
Note:Want more articles from this author? Scroll up to the top of this article and click the FOLLOW AUTHOR button to get an email each time a new article is published.
So Where Are the Profitable Trades?
Be sure to short or avoid this Bear Stock of the Day. Now would you like to see Zacks' recommendations that have the best profit potential? Starting today, for the next month, you can follow all our private buys and sells in real time from value to momentum . . . from stocks under $10 to ETF and option moves . . . from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for all Zacks trades >>